Urinary Diversion
Urinary diversion encompasses the reconstructive options used when the native bladder is removed, bypassed, or no longer suitable for storage and emptying. At a practical level, the major families are ileal conduit, colon conduit, orthotopic neobladder, continent cutaneous diversion, and cutaneous ureterostomy, each trading operative complexity, continence goals, metabolic burden, and long-term maintenance in different ways.
General Principles
- Principles of Urinary DiversionDetubularization, spherical reservoir design, bowel-segment physiology, ureteroenteric anastomosis, continence mechanisms, patient selection, metabolic surveillance, and lifelong follow-up.
- Intracorporeal Urinary Diversion (ICUD)Robotic step-by-step technique for the intracorporeal ileal conduit and orthotopic neobladder; Bricker vs Wallace; ICUD-vs-ECUD outcomes; learning curve.
Decision Framework
AUA 2024 Statement 13 calls for discussing ileal conduit, continent cutaneous diversion, and orthotopic neobladder with patients undergoing radical cystectomy.[1] Suitability depends on organ function, bowel availability, urethral/sphincter status, ability to manage the diversion, and patient goals. For orthotopic diversion after radical cystectomy for bladder cancer, a usable urethra and a negative urethral margin are prerequisites ; EAU 2026 strongly recommends against it when invasive tumour is in the urethra or at the urethral dissection level.[1][2] Renal and hepatic function, ability to manage the diversion, and patient preference also determine candidacy.[1][2]
| Decision | What to assess |
|---|---|
| Is continent diversion feasible and desired? | Renal/hepatic reserve, bowel condition, cognition, dexterity, willingness and ability to catheterize when needed, support and follow-up access |
| Is orthotopic reconstruction suitable? | Urethral cancer status, sphincter function, outlet patency, emptying requirements and the patient's acceptance of leakage or catheterization |
| Would a cutaneous pouch meet the patient's goals? | A catheterizable stoma avoids urethral dependence but requires reliable repeated catheterization and may need later revision |
| Is a conduit preferred? | Continuous drainage to an appliance can suit patients across ages and fitness levels; assess stoma care, bowel suitability and operative burden |
| Should bowel use be avoided? | Cutaneous ureterostomy is an option in selected patients, with counseling about stenosis, stents and upper-tract follow-up |
| Has radiation or previous surgery affected available bowel? | Review the actual treatment field, prior resections, vascular supply and tissue quality; no colonic segment is automatically outside the field or radiation-resistant |
| Is concurrent fecal diversion required? | Consider a colon conduit or colostomy-switch strategy with colorectal expertise; feasibility depends on the remaining anatomy and both stoma sites |
| Is renal or hepatic function substantially impaired? | Assess severity and reversible causes. Any urine-exposed bowel can impose a metabolic burden; an ileal conduit does not automatically remove this risk |
These are selection considerations. No fixed sequence based on age, ASA class or a single creatinine value applies. See Principles of Urinary Diversion for detailed contraindications and planning.[1][2]
Day-to-day differences
| Feature | Ileal conduit | Continent cutaneous pouch | Orthotopic neobladder |
|---|---|---|---|
| Urine exit | Abdominal stoma into an appliance | Catheterizable abdominal stoma | Native urethra |
| Emptying | Continuous drainage | Scheduled intermittent catheterization | Learned, scheduled emptying; catheterization may be needed |
| Continence goals | Reliable appliance fit and drainage | Dryness between catheterizations | Daytime and nighttime continence, assessed separately |
| Typical maintenance concerns | Stoma/appliance problems, obstruction, infection and metabolic effects | Channel access, stones, leakage, obstruction and metabolic effects | Residual urine, leakage, obstruction, stones and metabolic effects |
There is no established overall quality-of-life winner. Comparisons are strongly affected by patient selection, outcome definitions and follow-up.[3]
Pellegrino's retrospective study of 6,469 patients at 23 centers during 2004–2024 reported 56% ileal conduit, 31% neobladder and 14% cutaneous ureterostomy overall (rounded percentages). Neobladder use decreased from 41% to 19%, while ureterostomy increased from 2% to 22%.[4]
All diversions require long-term functional follow-up tailored to their anatomy; urine-exposed bowel also warrants metabolic assessment and, under EAU follow-up guidance, annual B12 measurement (no strength rating). Cancer surveillance is a separate, risk-based plan.[5]
Diversion Database
| Diversion | Family | Technique / clinical use |
|---|---|---|
| Ileal Conduit | Incontinent | Established continuous drainage option using an ileal segment and an external appliance |
| Cutaneous Ureterostomy | Incontinent | Bowel-free cutaneous drainage in selected patients; assess stenosis and stent burden |
| Colon Conduit | Incontinent | Selected viable colon when ileum is unsuitable or concurrent fecal diversion is needed |
| Hautmann Neobladder | Continent Orthotopic | W-configured ileal reservoir; plan low-pressure storage and reliable emptying |
| Modified Studer Pouch | Continent Orthotopic | Ileal neobladder with a tubular afferent limb and refluxing ureteral implantation |
| T-Pouch Modification | Continent Orthotopic | Tunneled afferent ileal limb; USC-STAR found no three-year renal advantage over Studer |
| Camey II Neobladder | Continent Orthotopic | Detubularized ileal reservoir connected to the native urethra |
| VIP (Vesica Ileale Padovana) Neobladder | Continent Orthotopic | Spherical ileal neobladder with antireflux ureteral implantation |
| Le Bag (Light & Engelmann) | Continent Orthotopic | Ileocolonic orthotopic reservoir |
| Mansoura Neobladder | Continent Orthotopic | Spherical ileal neobladder with serous-lined extramural ureteral tunnels |
| Sigmoid Colon Neobladder | Continent Orthotopic | Detubularized left-colon orthotopic substitute; alternative to an ileal neobladder |
| Indiana Pouch | Continent Cutaneous | Catheterizable ileocolonic reservoir for an appropriate continent-diversion candidate |
| Kock Pouch | Continent Cutaneous | Stand-alone ileal continent reservoir with intussuscepted nipple-valve continence (historical lineage) |
| Mainz Pouch I | Continent Cutaneous | Ileocecal reservoir with a catheterizable outlet; outlet construction varies |
| Mainz Pouch III | Continent Cutaneous | All-colon catheterizable reservoir from nonirradiated transverse colon, used after pelvic irradiation |
| Florida Pouch | Continent Cutaneous | Ileocecal continent diversion with tapered-ileum efferent limb |
| Double T-Pouch | Continent Cutaneous | Cutaneous ileal reservoir using separate T-valve inlet and catheterizable outlet mechanisms |
| Ureterosigmoidostomy | Continent Heterotopic | Diversion using the intact rectum as continent reservoir (historical; secondary-malignancy risk) |
| Mainz Pouch II (Sigma-Rectum Pouch) | Continent Heterotopic | Detubularized rectosigmoid reservoir; continence via anal sphincter |
| Colon Shuffle | Complex / Salvage | Colon conduit with relocation or creation of a separate fecal stoma |
Related Procedures
- Simple Cystectomy (Benign Disease): bladder removal for severe benign disease, including radiation injury, fistula, IC/BPS, or neurogenic conditions; commonly paired with a diversion.
- Parastomal Hernia Repair: prevention, assessment, and repair of a hernia around a urinary stoma.
See Also
- On WHITWIKI, the sister site for GU oncology: Urinary Diversion Selection and Bowel Principles, Radical Cystectomy.
References
1. American Urological Association / American Society of Clinical Oncology / Society of Urologic Oncology. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). Statement 13 and discussion. Guideline.
2. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2026. Section 6.7.5, urinary diversion and patient selection. Guideline.
3. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2026. Section 10.3, quality of life after cystectomy and urinary diversion. Guideline.
4. Pellegrino F, et al. Temporal trends and clinical determinants of urinary diversion after radical cystectomy. BJU Int. 2026;137(2):323-331. PubMed. doi:10.1111/bju.70018.
5. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2026. Section 7.4, follow-up of functional outcomes and complications. Guideline.